Revenue Performance - Total revenue for the three months ended September 30, 2024, increased by 34% to 5,599,000comparedto4,182,000 for the same period in 2023[152] - Revenue from Printed Products rose by approximately 46% to 4,828,000,drivenbynewcustomerorders[152]−Rentalincomesurgedby110496,000, attributed to new tenants at the AMRE LifeCare Pittsburg facility[152] - For the nine months ended September 30, 2024, total revenue decreased by 28% to 13,681,000comparedto18,920,000 for the same period in 2023[153] - Revenue from Printed Products for the nine months decreased by 12% due to delayed shipments and reduced orders from existing customers[153] - Rental income for the nine months fell by 61% as tenants at AMRE LifeCare struggled to make payments[153] - Biotechnology revenue surged by 150% to 10,000forthethreemonthsendedSeptember30,2024,comparedto4,000 in the same period last year[155] - Commission revenue reached 230,000,asignificantincreasefromzerointhepreviousyear[152]−Directmarketingrevenuedroppedtozero,reflectingastrategicshiftfrommaintainingasalesforcetolicensingproducts[152]CostsandExpenses−Totalcostsandexpensesincreasedby1110,270,000 for the three months ended September 30, 2024, compared to 9,285,000forthesameperiodin2023[155]−Otheroperatingexpensesincreasedby1123783,000 for the three months ended September 30, 2024, compared to 64,000inthesameperiodlastyear[155]−Professionalfeesdecreasedby322,206,000 for the nine months ended September 30, 2024, compared to 3,248,000forthesameperiodin2023[158]InvestmentandCashFlow−Netinvestmentincomedecreasedby5845,000 due to several loans going on non-accrual[152] - Cash used by operating activities was 9,181,000fortheninemonthsendedSeptember30,2024,downfrom21,035,000 for the same period in 2023[173] - Net cash provided by investing activities was 9,916,000fortheninemonthsendedSeptember30,2024,comparedto11,885,000 for the same period in 2023[174] - Interest income decreased by 96% to 28,000forthethreemonthsendedSeptember30,2024,comparedto682,000 for the same period in 2023[165] - The company had cash of approximately 11.6millionasofSeptember30,2024,sufficienttomeetcashrequirementsforatleastthenext12months[172]FinancialPerformance−NetlossfortheninemonthsendedSeptember30,2024,was15,762,000, a 52% improvement from a net loss of 33,061,000inthesameperiodin2023[170]InternalControlsandCompliance−AsofSeptember30,2024,thecompany′sdisclosurecontrolsandprocedureswerenoteffective,asdisclosedmaterialweaknessesfromtheAnnualReportonForm10−KfortheyearendedDecember31,2023remained[177]−Thecompanyhasaremediationplaninplacetoaddressmaterialweaknesses,withongoingimplementationstepsthatmaytaketimetofullyintegrateandconfirmeffectiveness[179]−Therewerenochangesinthecompany′sinternalcontroloverfinancialreportingduringthequarterendedSeptember30,2024,thatmateriallyaffecteditsinternalcontrols[180]CorporateChanges−ThecompanydeconsolidatedSharingServicesGlobalCorporation(SHRG)effectiveMay1,2023,resultinginasignificantimpactontheDirectMarketingsegment[139]ResearchandDevelopment−Researchanddevelopmentcostsdecreasedby9350,000 for the nine months ended September 30, 2024, compared to $684,000 for the same period in 2023[161]